Business Wire

IL-PROJECT44

4.3.2020 13:02:09 CET | Business Wire | Press release

Share
project44 Introduces First Ever Carrier Onboarding SLA to Accelerate Visibility Results for Shippers

According to Gartner Inc.’s recently released Market Guide for Real-Time Transportation Visibility Platforms , visibility is only possible with comprehensive network coverage and compliance. Today project44, the global leader in advanced visibility for shippers and logistics service providers, announced a new service level agreement (SLA) around full truckload carrier onboarding. This groundbreaking agreement demonstrates the technology provider’s commitment to results and offers a money-back guarantee.

Under the new carrier coverage SLA, project44 will guarantee that 90% of a shipper’s contracted truckload carriers in North America and Europe will be live within 30 days of starting implementation. With carrier compliance at the foundation of transportation visibility, this commitment will rapidly deliver upon the promise of real-time visibility and provide project44 customers a significant competitive advantage in today’s Delivery Economy.

“Carrier network coverage is the linchpin to visibility. Uline evaluated a variety of technology providers and knew that our full truckload visibility implementation would fail without adequate network coverage. It was very clear to us that p44 provided the largest carrier network along with the most scalable and automated onboarding process,” said Angelo Ventrone, VP of Logistics at Uline, the leading distributor of shipping, industrial and packaging materials in North America. “As a partner, they went above and beyond to ensure compliance, which has resulted in truckload tracking percentages of over 95%. Ultimately selecting project44 has enabled Uline to efficiently deliver on a differentiated customer experience.”

While this service level agreement is new to the industry, project44’s commitment to its carrier network is not. The visibility provider serves over 300 enterprise customers with the largest carrier network across North America and Europe. This includes connections to more than 760 ELD/telematics providers over more than 48 countries, and connections to 4.33 million drivers, 3.55 million trucks, and 800,000 fleets. Thanks to its automated onboarding application, the Network Management Center™, project44 enables customers to accelerate their time to value and immediately see the results of their visibility investment.

“Coop operates with more than 1,000 stores who all need deliveries on a weekly basis. For us to have the most efficient supply chain, we lacked an end-to-end overview of our carrier and subcontractor deliveries,” said Kennet Thorsen, Senior Distribution Manager at Coop Denmark A/S. “Our organization leveraged project44’s robust carrier network and world-class onboarding process to rapidly increase the ROI of our technology investment, streamline operations and better meet service goals towards our stores.”

project44's Network Management Center debuted in Europe over three years ago, driving unprecedented time-to-live with Truckload carriers. 48% of carriers achieve live status within one day, 81% within ten days – all through an automated, self-service cloud-based application. By combining project44’s automated tools and enterprise-grade implementation processes, the world’s leading ecommerce retailer, utilizing more than 2,500 different truckload providers across Europe, saw 95% connectivity in the first 45 days of working with project44. The commitment outlined in this SLA provides shippers of all sizes with the tools necessary to compete with even the largest ecommerce companies.

“Carrier coverage is critical to seeing the ROI of visibility, and project44 is dedicated to quickly achieving high compliance percentages for our customers. It has been our goal from day one to build global and multimodal connectivity and serve as the supply chain ecosystem’s connective tissue. This SLA formalizes our commitment, ensuring the entire industry truly understands the power the right visibility solution can have on delivering rapid and enduring results for the world’s leading retailers, manufacturers and distributors,” stated Tommy Barnes, Head of Global Network Partnerships at project44.

By following project44’s implementation program and best practices, project44 will offer the 30-day onboarding SLA with a money back guarantee to shippers in North America and Europe. To learn more about the SLA and project44’s Advanced Visibility Platform™, contact the project44 team today .

About project44

project44 is the world’s only advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye